Limertinib+bevacizumab

Phase 2Monoclonal antibody

SShanghai Chest Hospital

Limertinib+bevacizumab is one of 51 small molecule programs targeting First-line Treatment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

First-Line TreatmentNot yet recruiting

First-Line TreatmentPhase 2

Not yet recruiting

Competition

Competitive Landscape

74 competitors in First-Line Treatment

#DrugCompanyPhaseTrials

Gemzar

Johnson & Johnson

Phase 3

4 2

Lexapro

AbbVie

Phase 3

1 3

Tuoyi

SSun Yat-sen University

Phase 3

6 4

Vepesid

AAvyxa

Phase 3

3 5

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

2 6

Adstiladrin

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

2 7

Lithobid

SSolvay Pharmaceuticals

Phase 3

1 8

Effexor

WWyeth-Lederle Vaccines

Phase 3

1 9

Wellbutrin

GGlaxo Dba Glaxosmithkline

Phase 3

1 10

Seroquel

EEngelhard Arzneimittel GmbH & Co.KG

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Not yet recruiting

First-Line Treatment

NCT06982924

Clinical

Trials by Indication[1]

First-line Treatment1 trial

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.

Not yet recruiting·SShanghai Chest Hospital·Phase 2·NCT06982924·136 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Limertinib+bevacizumab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Limertinib+bevacizumab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Limertinib+bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Chest Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 2[1]
Company: SShanghai Chest Hospital

Limertinib+bevacizumab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

First-line Treatment1 trial

References

Drug Info

Quick Facts

Related News